Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst DayGlobeNewsWire • 10/22/26
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic EsophagitisGlobeNewsWire • 10/15/26
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical ConferencesGlobeNewsWire • 10/09/26
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic EsophagitisGlobeNewsWire • 09/30/26
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor ConferencesGlobeNewsWire • 09/08/26
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis PatientsGlobeNewsWire • 08/13/26
Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High?Zacks Investment Research • 08/10/26
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of GrowthGlobeNewsWire • 07/13/26
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and CommercializationGlobeNewsWire • 07/07/26
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of ShareholdersGlobeNewsWire • 06/19/26
Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/28/26
Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease WeekGlobeNewsWire • 05/06/26
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)GlobeNewsWire • 05/05/26
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter OptionGlobeNewsWire • 02/20/26
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded WarrantsGlobeNewsWire • 02/19/26
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on BiopsyGlobeNewsWire • 01/08/26
Wall Street Analysts Think Eupraxia Pharmaceuticals Inc. (EPRX) Could Surge 75.08%: Read This Before Placing a BetZacks Investment Research • 11/14/25